New Multi-Drug attack on tough rectal cancer recurrence
NCT ID NCT07183865
Summary
This study is testing a combination of radiation, chemotherapy, immunotherapy, and targeted drugs for rectal cancer that has come back in the pelvic area after previous treatment. It is for patients whose cancer progressed or who could not tolerate a standard chemotherapy drug called oxaliplatin. The goal is to see if this intensive approach can shrink the tumors enough to allow for possible surgery or provide long-term control of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.